| Project/Area Number |
26293216
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Partial Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Metabolomics
|
|---|
| Research Institution | The University of Tokyo |
|---|
Principal Investigator |
Iwabu Miki 東京大学, 医学部附属病院, 特任講師 (70392529)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
IWABU Masato 東京大学, 医学部附属病院, 特任准教授 (30557236)
YAMAUCHI Toshimasa 東京大学, 医学部附属病院, 准教授 (40372370)
KADOWAKI Takashi 東京大学, 医学部附属病院, 教授 (30185889)
TOKOYAMA Shigeyuki 独立行政法人理化学研究所, 横山構造生物学研究室, 上席研究員 (00159229)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥16,900,000 (Direct Cost: ¥13,000,000、Indirect Cost: ¥3,900,000)
Fiscal Year 2016: ¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2015: ¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2014: ¥8,840,000 (Direct Cost: ¥6,800,000、Indirect Cost: ¥2,040,000)
|
|---|
| Keywords | 糖尿病 / 薬理学 / トランスレーショナルリサーチ |
|---|
| Outline of Final Research Achievements |
We have so far clarified that adiponectin, an adipocyte-secreted physiologically active substance, is decreased with the onset of obesity and that lifestyle-related diseases are primarily accounted for by the systemically decreased action of adiponectin/adiponectin receptors (AdipoRs). We were the first in the world to succeed in identifying small-molecule compounds that serve as seed compounds for candidate AdipoR-activating drugs. In the process, we have also reported the crystal structures of AdipoRs, which allowed the seed compounds to be structurally developed, examined for their anti-diabetic properties at the cellular and organism levels, and optimized as candidate compounds for clinical development, with their activity, specificity and safety highly enhanced over those of existing small-molecule AdipoR-activating compounds. It is hoped that these milestones will lead to the development of novel anti-diabetic drugs.
|
